| 前收市價 | 1.5800 |
| 開市 | 1.8700 |
| 買盤 | 1.6500 |
| 賣出價 | 2.0000 |
| 拍板 | 7.50 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 1.8700 - 1.8700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 63 |
ZacksAmgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
ZacksAbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
ZacksAgios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
